A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...

Researchers have unveiled a way to flip genes back on without slicing into the genome, a shift that could make CRISPR far ...

Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials. Editas ...

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there. It's also going to be facing down ...